Results 91 to 100 of about 9,857 (174)
In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi +6 more
doaj +1 more source
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J +9 more
doaj
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj +1 more source
Will Ceftazidime-Avibactam Replace Polymyxins in Asia?
Sock Hoon, Tan +3 more
openaire +2 more sources
We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop.
Amadesi S. +5 more
openaire +2 more sources
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie +5 more
doaj +1 more source
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy +5 more
doaj +1 more source
The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting
BACKGROUND: Ceftazidime-avibactam (CZA) represents a novel therapeutic approach for combating infections caused by multidrug-resistant Gram-negative bacteria. With the rise of antimicrobial resistance posing a significant challenge in hospital settings, this study aims to evaluate the utilization of CZA in hospitals and its subsequent outcomes. METHODS:
Shobana Selvaganesan +2 more
openaire +2 more sources
BackgroundGlobal surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level
Shulong Zhao +6 more
doaj +1 more source

